Cardiologia Croatica, Vol. 7 No. 1-2, 2012.
Professional paper
Advantages of perindopril as monotherapy and combinations with indapamide compared to other ACE inhibitors in cardiovascular patients
Mario Pehar
; Clinical Hospital Dubrava, Zagreb, Croatia
Abstract
Angiotensin-converting enzyme (ACE) inhibitors play a key role in the treatment of patients along the entire cardiovascular continuum from uncomplicated hypertension to developed coronary artery disease and myocardial disease. Based on the conducted randomized clinical trials, we can conclude that they have a significant cardiac and vasoprotective effect in addition to the basic antihypertensive effect. It is important to note that within the class of ACE inhibitors, perindopril is characterized by its very significant effects on improvement of endothelial function, thereby inhibiting pathophysiological process from the outset. The combination of perindopril with the diuretic – indapamide is logical given that their combined effect is additive, that is, it results in an optimal control of the renin angiotensin-aldosterone system and strong anti-hypertensive reaction. Perindopril and ramipril have clearly demonstrated the reduction of cardiovascular risk in randomized clinical trials in the group of patients with stable angina pectoris, whereas quinapril and trandolapril did not show the above effect. Of all cardiovascular drugs, ACE inhibitors have the highest level of evidence in terms of prevention of cardiovascular events during the entire spectrum of cardiovascular diseases. Krka’s perindopril, or a fixed combination of perindopril with indapamide is available in different dosages and packaging, making it the optimal choice on the market.
Keywords
hypertension; angiotensin-converting enzyme inhibitors; perindopril; indapamide
Hrčak ID:
77051
URI
Publication date:
26.1.2012.
Visits: 4.035 *